Nicox
en
Toggle Menu
About Us
Visible Science
Leadership Team
Board of Directors
Glaucoma Advisory Board
Partnerships
Portfolio and Disease Areas
Nicox’s innovative portfolio
Disease focus areas
Our portfolio at a glance
Nitric Oxide Donation
Publications
Investors
Stock Information
Financial and Regulatory Information
Shareholder Meetings
Corporate Presentation
Questions & Answers
Webcasts
Corporate Governance
News and Events
Press Releases
Events and Conferences
Videos
Contact Us
Contact Details
Main subsidiaries
Job opportunities
Email alerts
Nicox : Recrutement terminé dans l’étude clinique de phase 2 pour le NCX 4251 – Premiers résultats attendus au quatrième trimestre 2019
July 18, 2021
← Back to blog page
Cookies
By continuing to use this website, you agree to our
Cookie Policy
.
Accept
